Abstract
Studies utilizing the 28 amino acid vasoactive intestinal peptide (VIP), or glial-derived VIP-associated proteins as templates for future drug design originated from two lines of experimental results: 1] The findings of increased expression of the VIP gene (Bodner et al.,1985) during synapse formation (Gozes et al., 1987) and its decreased synthesis with aging (Gozes et al.,1988). 2] The findings of neuroprotective activities for VIP against electrical blockade (Brenneman and Eiden, 1986) that are mediated by glial cells (Brenneman et al.,1987; Brenneman et al.,1990) expressing high affinity VIP receptors (Gozes et al.,1991).
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Ashur-Fabian, O., Perl, O., Lilling, G., Fridkin, M., and Gozes, I. 1999, SNV, a lipophilic superactive VIP analog, acts through cGMP to promote neuronal survival. Peptides 20: 629–633.
Bodner, M., Fridkin, M., and Gozes, I. 1985 Coding sequences for vasoactive intestinal peptide and PHM-27 peptide are located on two adjacent exons in the human genome. Proc. Natl. Acad. Sci. U S A 82: 3548–3551.
Bassan, M., Zamostiano, R., Davidson, A., Pinhasov, A., Giladi, E., Perl, O., Bassan, H., Blat, C., Gibney, G., Glazner, G., Brenneman, D.E., and Gozes, I. 1999, Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide. J. Neurochem. 72: 1283–1293.
Brenneman, D.E., and Eiden, L.E., 1986, Vasoactive intestinal peptide and electrical activity influence neuronal survival. Proc. Natl. Acad. Sci. U S A 83: 1159–1162.
Brenneman, D.E., Neale, E.A., Foster, G.A., d’Autremont, S.W., and Westbrook, G.L. 1987, Nonneuronal cells mediate neurotrophic action of vasoactive intestinal peptide. J. Cell Biol. 104: 1603–1610.
Brenneman, D.E., Nicol, T., Warren, D., and Bowers, L.M. 1990, Vasoactive intestinal peptide: a neurotrophic releasing agent and an astroglial mitogen. J. Neurosci. Res. 25: 386–394.
Brenneman, D.E., and Gozes, I. 1996, A femtomolar-acting neuroprotective peptide. J. Clin. Invest. 97: 2299–2307.
Brenneman, D.E., Hauser, J., Neale, E., Rubinraut, S., Fridkin, M., Davidson, A., and Gozes, I. 1998, Activity-dependent neurotrophic factor: structure-activity relationships of femtomolar-acting peptides. J. Pharmacol. Exp. Ther. 285: 619–627.
Fisher, A., Brandeis, R., Pittel, Z., Karton, I., Sapir, M., Dachir, S., Levy, A., and Heldman, E. 1989, (+-)-cis-2-methyl-spiro(l, 3-oxathiolane-5, 3’) quinuclidine (AF102B): a new M1 agonist attenuates cognitive dysfunctions in AF64A-treated rats. Neurosci. Lett. 102: 325–331.
Gozes, I., Shani, Y., and Rostene, W.H. 1987, Developmental expression of the VIP-gene in brain and intestine. Brain Res. 388: 137–148.
Gozes, I., Schachter, P., Shani, Y., Giladi, E. 1988, Vasoactive intestinal peptide gene expression from embryos to aging rats. Neuroendocrinology 47: 27–31.
Gozes, I., McCune, S.K., Jacobson, L., Warren, D., Moody, T.W., Fridkin, M., and Brenneman, D.E., 1991, An antagonist to vasoactiveintestinal peptide: effects on cellular functions in the central nervous system. J. Pharmacol. Exp. Ther. 257: 959–966.
Gozes, I., Lilling, G., Glazer, R., Ticher, A., Ashkenazi, I.E., Davidson, A., Rubinraut, S., Fridkin, M., and Brenneman, D.E. 1995, Superactive lipophilic peptides discriminate multiple vasoactive intestinal peptide receptors. J. Pharmacol. Exp. Ther. 273: 161–167.
Gozes, I., Bardea, A., Reshef, A., Zamostiano, R., Zhukovsky, S., Rubinraut, S., Fridkin, M., and Brenneman, D.E. 1996a, Novel neuroprotective strategy for Alzheimer’s disease: inhalation of a fatty neuropeptide. Proc. Natl. Acad. Sci. U S A 93: 427–432.
Gozes, I., and Brenneman, D.E. 1996b, Activity-dependent neurotrophic factor (ADNF): An extracellular neuroprotective chaperonin? J. Molec. Neurosci. 7: 235–244.
Gozes, I., Davidson, A., Gozes, Y., Mascolo, R., Barth, R., Warren, D., Hauser, J., and Brenneman, D.E. 1997, Antiserum to activity-dependent neurotrophic factor produces neuronal cell death in CNS cultures: immunological and biological specificity. Develop. Brain Res. 99: 167–175.
Gozes, I., Perl, O., Giladi, E., Davidson, A., Ashur-Fabian, O., Rubinraut, S., and Fridkin, M. 1999, Mapping the active site in vasoactive intestinal peptide to a core of four amino acids: neuroprotective drug design. Proc. Natl. Acad. Sci. U S A 96: 4143–4148.
Gozes, I., Giladi, E., Pinhasov, A., Bardea, A., and Brenneman, D.E. 2000, Activitydependent neurotrophic factor: intranasal administration of femtomolar-acting peptides improve performance in a water maze. J. Pharmacol. Exp. Ther. 293: 1091–1098.
Zamostiano, R., Pinhasov, A., Gelber, E., Steingart, R.A., Seroussi, E., Giladi, E., Bassan, M., Wollman, Y., Eyre, H.J., Mulley, J.C., Brenneman, D.E., and Gozes, I. 2000, Cloning and Characterization of the Human Activity-Dependent Neuroprotective Protein (ADNP). J. Biol. Chem. in press.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 Springer Science+Business Media New York
About this chapter
Cite this chapter
Gozes, I. et al. (2001). Intranasal Delivery of Bioactive Peptides or Peptide Analogues Enhances Spatial Memory and Protects Against Cholinergic Deficits. In: Kobiler, D., Lustig, S., Shapira, S. (eds) Blood—Brain Barrier. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-0579-2_28
Download citation
DOI: https://doi.org/10.1007/978-1-4615-0579-2_28
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-5141-2
Online ISBN: 978-1-4615-0579-2
eBook Packages: Springer Book Archive